We are grateful to Siraj A Misbah amd Praveen Weeratunga for their comments on our study of patient-reported quality of life in children and young adults treated with tisagenlecleucel for B-cell acute lymphoblastic leukaemia. They correctly highlight that most patients in our ELIANA trial received immunoglobulin replacement and suggest that this might have contributed to the improvements in quality of life seen after treatment with tisagenlecleucel in our analysis of patients treated on this study.

中文翻译：

---

CAR T细胞治疗后免疫球蛋白的替代和生活质量-作者的回复。

我们感谢Siraj A Misbah和Praveen Weeratunga对我们报告的使用替沙吉列细胞治疗B细胞急性淋巴细胞白血病的儿童和年轻人的生活质量的评论，感谢他们的评论。他们正确地指出，在我们的ELIANA试验中，大多数患者都接受了免疫球蛋白替代治疗，并暗示这可能有助于在我们研究中分析了使用替沙三烯核苷治疗后所观察到的生活质量的改善。